August 12th, 2015

A Chinese Ebola Drug and IP Interplay

On June 11, 2015, the New York Times reported that a small Chinese company had produced 100 doses of an Ebola drug that closely mirrored a drug patented by a U.S. drug-maker and for which the U.S. government held a patent on one of the constituent antibodies. According to the article, a U.S. government official […]

Fordham IP Institute